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ORIGINAL ARTICLE
Integrin alpha 11 in the regulation of the myoﬁbroblast
phenotype: implications for ﬁbrotic diseases
Ruchi Bansal1, Shigeki Nakagawa2,3, Saleh Yazdani1, Joop van Baarlen4, Anu Venkatesh2,3, Anna P Koh2,3,
Won-Min Song2,3, Nicolas Goossens2,3, Hideo Watanabe5, Mary B Beasley3,6, Charles A Powell7, Gert Storm1,8,
Naftali Kaminski9, Harry van Goor10, Scott L Friedman2,3, Yujin Hoshida2,3 and Jai Prakash1,11,12
Tissue ﬁbrosis, characterized by excessive accumulation of aberrant extracellular matrix (ECM) produced by myoﬁbroblasts, is a
growing cause of mortality worldwide. Understanding the factors that induce myoﬁbroblastic differentiation is paramount to
prevent or reverse the ﬁbrogenic process. Integrin-mediated interaction between the ECM and cytoskeleton promotes
myoﬁbroblast differentiation. In the present study, we explored the signiﬁcance of integrin alpha 11 (ITGA11), the integrin alpha
subunit that selectively binds to type I collagen during tissue ﬁbrosis in the liver, lungs and kidneys. We showed that ITGA11
was co-localized with α-smooth muscle actin-positive myoﬁbroblasts and was correlatively induced with increasing ﬁbrogenesis
in mouse models and human ﬁbrotic organs. Furthermore, transcriptome and protein expression analysis revealed that
ITGA11 knockdown in hepatic stellate cells (liver-speciﬁc myoﬁbroblasts) markedly reduced transforming growth factor β-induced
differentiation and ﬁbrotic parameters. Moreover, ITGA11 knockdown dramatically altered the myoﬁbroblast phenotype, as
indicated by the loss of protrusions, attenuated adhesion and migration, and impaired contractility of collagen I matrices.
Furthermore, we demonstrated that ITGA11 was regulated by the hedgehog signaling pathway, and inhibition of the hedgehog
pathway reduced ITGA11 expression and ﬁbrotic parameters in human hepatic stellate cells in vitro, in liver ﬁbrosis mouse
model in vivo and in human liver slices ex vivo. Therefore, we speculated that ITGA11 might be involved in ﬁbrogenic signaling
and might act downstream of the hedgehog signaling pathway. These ﬁndings highlight the signiﬁcance of the ITGA11 receptor
as a highly promising therapeutic target in organ ﬁbrosis.
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INTRODUCTION
Fibrosis or excessive extracellular matrix (ECM) accumulation
results in the distortion of tissue architecture and organ dysfunc-
tion. Fibrotic diseases are the major cause of increasing morbidity
and mortality, contributing to 45% of deaths worldwide.1
Myoﬁbroblasts are the major ECM-producing cells in many
pathological conditions, including organ ﬁbrosis and cancer.2–5
Myoﬁbroblasts, depending on the etiology and organ,1,6 are
derived from various cell types, including resident ﬁbroblasts,
stellate cells, bone marrow-derived mesenchymal stem cells,
epithelial cells via the epithelial–mesenchymal transition7–9 and
endothelial cells via the endothelial–mesenchymal transition10
processes. In addition to ECM production and remodeling,
myoﬁbroblasts provide tissue stiffness due to their contractile
nature and elicit pro-angiogenic and pro-inﬂammatory signals in
the form of cytokines and growth factors.1,3,6,11,12 Myoﬁbroblasts
are therefore an attractive and promising cellular target for the
diagnosis of ﬁbrotic diseases and potential antiﬁbrotic
therapies.13–15
Interactions between cells and their extracellular microen-
vironment are primarily mediated by a family of cell surface
receptors known as integrins, which are recognized as key
1Targeted Therapeutics, Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, Faculty of
Science and Technology, University of Twente, Enschede, The Netherlands; 2Division of Liver Diseases, Department of Medicine, Liver Cancer Program,
Tisch Cancer Institute, New York, NY, USA; 3Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 4Laboratorium
Pathologie Oost-Nederland, Hengelo, The Netherlands; 5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston,
MA, USA; 6Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 7Division of Pulmonary, Critical Care, and Sleep
Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 8Department of Pharmaceutics, Utrecht Institute of Pharmaceutical Sciences,
Faculty of Science, Utrecht University, Utrecht, The Netherlands; 9Yale School of Medicine, Pulmonary, Critical Care and Sleep Medicine, New Haven, CT,
USA; 10Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands;
11Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden and 12ScarTec Therapeutics BV, Enschede, The Netherlands
Correspondence: Dr R Bansal or Dr J Prakash, Targeted Therapeutics, Department of Biomaterials, Science and Technology, MIRA Institute for Biomedical
Technology and Technical Medicine, University of Twente, Drienerlolaan 5, Enschede 7522 NB, The Netherlands.
E-mail: R.Bansal@utwente.nl or J.Prakash@utwente.nl
Received 9 December 2016; revised 18 April 2017; accepted 14 May 2017
Experimental & Molecular Medicine (2017) 49, e396; doi:10.1038/emm.2017.213
Ofﬁcial journal of the Korean Society for Biochemistry and Molecular Biology
www.nature.com/emm
molecules involved in myoﬁbroblast differentiation.16,17
Integrins are heterodimeric transmembrane receptors
composed of α and β subunits that can combine to form 24
different integrin heterodimers.18 Integrins regulate cytoskeletal
dynamics, thereby inﬂuencing a number of crucial cellular
processes, for example, cell adhesion, migration and
differentiation.19 Integrins also have a key role in the activation
of growth factors such as transforming growth factor beta
(TGFβ); for instance, RGD-binding αv integrins have been
shown to be master regulators of TGFβ activation in different
ﬁbrotic models.17,20,21 Because integrins have profound effects
on ﬁbrosis in multiple organs, it might be, therefore, of utmost
importance to understand/elucidate the regulatory roles of
integrins and to deﬁne the strategies of modulating integrins
for the development of effective antiﬁbrotic approaches.
Accumulation of collagens (predominantly collagen I) in
liver ﬁbrosis and other ﬁbrotic tissues is a common
characteristic in ﬁbrotic diseases. Among four collagen
receptors, α1β1, α2β1, α10β1 and α11β1,22 integrin α11β1
preferentially binds to type I collagen23 and has been shown to
be expressed on cultured embryonic ﬁbroblasts24 and cardiac
ﬁbroblasts.25 α11β1 has been shown to be upregulated by
TGFβ26,27 and regulates embryonic mesenchymal cell
differentiation on the collagen matrix.25,27,28 More recently,
the role of integrin α11β1 was implicated in inducing tumor
growth and the metastatic potential of small-cell lung
carcinoma cells.29 However, the functional signiﬁcance of
integrin alpha 11 (ITGA11), its cellular distribution and
contribution to ﬁbrotic diseases remains largely undeﬁned.
In this study, we examined the expression and localization of
ITGA11 in human organ ﬁbrosis, including liver cirrhosis,
renal ﬁbrosis and lung ﬁbrosis, and have assessed the
signiﬁcance of ITGA11 during TGFβ-induced trans-
differentiation of hepatic stellate cells to myoﬁbroblasts.
Furthermore, we investigated the signaling pathway that
regulates ITGA11 expression and liver ﬁbrogenesis.
MATERIALS AND METHODS
Human tissues
Human liver specimens were obtained from the autopsy of patients
with liver cirrhosis (n= 5) anonymously provided by the Laboratory
Pathology Netherlands (LabPON) and Mount Sinai Hospital, New
York, USA. Normal liver tissue (n= 4) was collected from patients
receiving hepatic resections for non-tumoral diseases, including
hepatic adenoma and focal nodular hyperplasia. Nephrectomy
specimens (n= 4) used in this study were obtained from renal
transplant recipients with chronic transplant dysfunction and were
anonymously provided by the Department of Internal Medicine,
Division of Nephrology, University Medical Center Groningen,
Groningen, The Netherlands. Fibrotic (n= 5) and non-ﬁbrotic
(n= 5) lung tissues were collected at Mount Sinai Hospital from the
patients with lung disease, including pneumothorax and lung cancer.
Upon Institutional Review Board approval and after written informed
consent from patients, the tissue specimens were collected. The use of
human tissues was approved by the respective Local Medical Ethics
Committee, and the experimental protocols were performed in
accordance with institutional guidelines and regulations.
Cell lines
Primary Human hepatic stellate cells (HSCs) were purchased from
Zen-Bio (Durham, NC, USA) and were grown in stellate cell growth
medium SteCM (ScienCell, Carlsbad, CA, USA) according to the
manufacturer’s instructions. HepG2 and THP1 cells were purchased
from ATCC (Manassas, VA, USA) and ECACC (Sigma, St Louis, MO,
USA), respectively, and were cultured in Dulbecco’s modiﬁed Eagle’s
medium and RPMI-1640 medium (Lonza, Verviers, Belgium),
supplemented with 2 mM L-glutamine, 10% fetal bovine serum
(FBS, Lonza) and antibiotics (50 U ml− 1 Penicillin and 50 μg ml− 1
streptomycin, Sigma) respectively. No cell line used in this paper is
listed in the database of commonly misidentiﬁed cell lines that is
maintained by the International Cell Line Authentication Committee
(http://iclac.org/databases/cross-contaminations/). All cell lines were
tested negative for mycoplasma contamination.
Stable ITGA11 knockdown in HSCs
To generate stable ITGA11 knockdown (ITGA11-KD) cells, primary
HSCs were transfected with lentiviral shRNA ITGA11 plasmids
(Santa Cruz Biotechnology, Dallas, TX, USA) using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) as per the manufacturer’s
instructions. Control cells were transfected with control/scrambled
shRNA plasmid. After 24 h of transfection, stably transfected cells were
selected by 2 μg ml− 1 puromycin (Invitrogen) for 6–8 weeks. ITGA11-
KD and control cells were evaluated for the effects on contractility,
migration/wound healing and several ﬁbrotic parameters using
staining and quantitative PCR (qPCR).
3D collagen-I gel contraction assay
A collagen suspension (5 ml) containing 3.0 ml of collagen G1
(5 mgml− 1, Matrix Biosciences, Morlenbach, Germany), 0.5 ml of
10× M199 medium (Sigma), 85 μl of 1 N NaOH (Sigma) and sterile
water was mixed with 1.0 ml (2× 106) of cells. The collagen gel and
cell suspension (0.6 ml per well) was plated in a 24‐well culture plate
and was allowed to polymerize for 1 h at 37 °C. For the effect studies,
polymerized gel was incubated with 1 ml of 0.5% FBS-containing
medium with or without human recombinant TGFβ (5 ng ml− 1)
(Peprotech, Rocky Hill, NJ, USA) together with 10 μM LDE225
(Erismodegib, Selleckchem, Boston, NY, USA) followed by detach-
ment of the gels from the culture wells. For other experiments,
medium with or without TGFβ was added before gel detachment.
Photographs were made with a digital camera at different time points
(0, 24, 48 and 72 h). The size of the gels was digitally measured and
normalized with their respective well size in each image. Gel
contraction experiments were performed in duplicate in three
independent experiments.
Wound-healing assay
Cells were plated in 12-well culture plates (1× 105 cells per well) for
24 h and were starved overnight in 0.5% FBS-containing medium.
A standardized scratch was made using a 200-μl pipette tip ﬁxed in a
holder. Cells were then washed twice and were incubated with and
without 5 ng ml− 1 TGFβ. To measure the migratory response of the
cells into the scrape wounds, microscopic photographs were taken at 0
and 24 h. Images were analyzed using NIH ImageJ software
(NIH, Bethesda, MD, USA) to calculate the area of the scratch wound
and were represented as the percentage of wound healed relative to the
control wells. Wound-healing experiments were performed in
duplicate in three independent experiments.
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Alamar blue assay
To assess the effects on proliferation, cells (control HSCs and ITGA11-
KD HSCs) plated in 96-well plates were serum starved for 24 h and
were then incubated with fresh medium with or without TGFβ
(5 ng ml− 1) for 24 and 48 h. At the indicated time points, cells were
incubated with Alamar Blue reagent (Invitrogen) for 4 h. The results
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are represented as the percentage of cell viability. All measurements
were performed in duplicate in four independent experiments.
Hedgehog parameters and the effect of hedgehog ligand on
human control HSCs and ITGA11-KD HSCs
Cells were seeded in 12-well plates (8× 104 cells per well) and were
cultured overnight. Cells were serum-starved for 24 h and then were
incubated with 5 μg ml− 1 of Shh ligand (Peprotech) for 24 h. Cells
were lysed with RNA lysis buffer to perform quantitative real-time
PCR analysis for hedgehog signaling pathway parameters and ITGA11
expression. qPCR analysis was performed in at least three independent
experiments.
In vitro effects of Hedgehog inhibitor in human HSCs
Cells were seeded in 24-well plates (3× 104 cells per well for staining)
and 12-well plates (8× 104 cells per well for qPCR analysis) and were
cultured overnight. To assess the effects on ﬁbrotic parameters, cells
were serum-starved for 24 h and then were incubated with starvation
medium alone, 10 μM LDE225 (Erismodegib) and 5 ng ml− 1 TGFβ1
for 24 h. Cells (24-well plates) were then ﬁxed with chilled acetone:
methanol (1:1) for 20 min, dried and stained for collagen-I, alpha
smooth muscle actin (α-SMA) and vimentin (refer to Supplementary
Table 1). In addition, cells (12-well plates) were lysed with RNA lysis
buffer to perform quantitative real-time PCR analyses. Staining and
qPCR analysis was performed in at least three independent
experiments.
Atomic force microscopy (AFM)
All AFM measurements were carried out using a Bioscope Catalyst
AFM with a Nanoscope V controller (Bruker, Santa Barbara, CA, USA)
mounted on an inverted microscope (Axiovert 200, Carl Zeiss,
Heidelberg, Germany). The AFM instrument was equipped with a
150×150 μm2 scanner with a vertical range of 25 μm. The optical
microscope was used to select the desired cell and to position the
AFM tip. A rectangular silicon nitride cantilever (NSC36, type C,
MikroMasch, Wetzlar, Germany) with a force constant of ∼ 0.6 Nm− 1
was used. Fixed cells (ﬁxed using 4% paraformaldehyde) were imaged
with 512×512 pixels2 in the contact mode in air at a scan rate of 1 Hz.
Multiple scans were acquired to image the whole cell. At least 4–5 cells
per condition were imaged to obtain representative images. All the AFM
images were processed by the Nanoscope Analysis software (Bruker).
Ex vivo organotypic culture of clinical liver tissue
De-identiﬁed liver tissues were obtained from liver surgeries
performed at Mount Sinai Medical Center, and anonymous use was
approved by the institutional review board. Fresh liver tissues were
sliced into 300-μm-thick tissue sections using the Krumdieck Tissue
Slicer MD6000 (Alabama Research and Development, Munford, AL,
USA) and were cultured with Williams’ medium E supplemented with
10% FBS, 100 Uml− 1 penicillin, 100 μg ml− 1 streptomycin and
2.5 μg ml− 1 amphotericin B on a heated shaker (37 °C) with medium
alone, 10 μM or 15 μM LDE225 for 48 h as described earlier.30
Harvested tissues were snap-frozen for RNA extraction.31 These
experiments were performed in three patients (n= 3) with three liver
slices per patient individually treated and combined for further
analysis.
Animal experiments
All the animal experiments in this study were performed in strict
accordance with the guidelines and ethical regulations for the Care and
Use of Laboratory Animals, Utrecht University, The Netherlands.
The protocols were approved by the Institutional Animal Ethics
Committee of the University of Twente, The Netherlands.
CCl4-induced liver ﬁbrosis mouse model
Male C57BL/6 mice (8–10-week old; n= 5 per group) were treated
with intraperitoneal injections with olive oil or carbon tetrachloride
(CCl4, 1 ml kg
− 1 prepared in olive oil) twice weekly for 8 weeks and
killed, and then the livers and other organs were collected for
subsequent analysis.
CCl4-induced acute liver injury mouse model
Male C57BL/6 mice were treated with a single intraperitoneal injection
of olive oil or CCl4 (1 ml kg
− 1 in olive oil) at day 1. At days 2 and 3,
CCl4-treated mice received subcutaneous administration of
10 mg kg− 1 Hedgehog inhibitor LDE225 prepared in 1% dimethyl
sulfoxide and 5% β-hydroxycyclodextrin or vehicle treatment
(1% dimethyl sulfoxide/5% β-hydroxycyclodextrin/phosphate-
buffered saline) (n= 5 per group). At day 4, all mice were killed,
and the livers were harvested.
UUO kidney ﬁbrosis mouse model
Male C57Bl/6 mice (8–10 weeks old, n= 5 per group) were subjected
to unilateral ureteral obstruction (UUO) by double ligation of the left
ureter proximal to the kidney. Right kidneys were used as contralateral
controls. Kidneys were harvested 3 and 7 days after surgery.
Immunohistochemistry and immunoﬂuorescence
Liver tissues were harvested and transferred to Tissue-Tek OCT
embedding medium (Sakura Finetek, Torrance, CA, USA) and
snap-frozen in 2-methyl butane chilled in dry ice. Cryosections
(4 μm) were cut using a Leica CM 3050 cryostat (Leica Microsystems,
Figure 1 Upregulation of ITGA11 in CCl4-induced chronic liver ﬁbrosis in mice and ﬁbrotic human livers. (a) Collagen-I, Desmin and
ITGA11-stained liver sections from olive-oil-treated (control) and CCl4-treated (8 weeks, ﬁbrotic) mice. n=5 per group. (b) Gene expression
of ﬁbrotic parameters (Col1a1, Col3a1, Tgfβ, Timp1, Mmp9 and Mmp13), myoﬁbroblast activation markers (Acta2, Desmin and Pdgfβr)
and Itga11 and Itgb1 in the livers of olive-oil-treated non-ﬁbrotic control mice and CCl4-treated ﬁbrotic mice (4 and 8 weeks). n=5 per
group. #Po0.05 and ##Po0.01 versus control. (c) Correlative analysis of ITGA11 protein and gene expression with respect to the
expression of ﬁbrotic parameters (collagen-I and Desmin). The correlations were assessed using Pearson’s correlative analysis. ‘R2’ denotes
Pearson’s correlation coefﬁcient, and ‘P’ denotes statistical signiﬁcance. (d) α-SMA- and ITGA11-stained human liver sections (n=4). Left,
healthy human liver; middle, cirrhotic human liver; right, magniﬁed image. Upper, ITGA11 (red); middle, α-SMA (green); bottom, merged
image. Nuclei are stained blue with DAPI. (e) ITGA11 mRNA expression levels from publicly available transcriptome proﬁling data sets
(www.ncbi.nlm.nih.gov/geo). Liver tissues affected with non-alcoholic fatty liver disease (NAFLD) stratiﬁed according to ﬁbrosis stage: stage
F0 or F1, mild ﬁbrosis (n=40); stage F3 or F4, severe ﬁbrosis (n=32) (GEO accession number: GSE49541).
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Nussloch, Germany). The sections were air-dried and ﬁxed with
acetone for 10 min. Cells or tissue sections were rehydrated with
phosphate-buffered saline and were incubated with the primary
antibody (refer to Supplementary Table 1) for 1 h at room tempera-
ture. Cells or sections were then incubated with horseradish
peroxidase-conjugated secondary antibody for 1 h at room tempera-
ture. Next, the samples were incubated with horseradish peroxidase-
conjugated tertiary antibody or donkey anti-goat Alexa 594-labeled
tertiary antibody (Life Technologies, Gaithersburg, MD, USA) for 1 h,
followed by washing three times with 1× phosphate-buffered saline.
Thereafter, peroxidase activity was developed using the AEC
(3-amino-9-ethyl carbazole) Substrate Kit (Life Technologies) for
20 min, and nuclei were counterstained with hematoxylin (Fluka
Chemie, Buchs, Switzerland). For tissue sections, endogenous perox-
idase activity was blocked by 3% H2O2 prepared in methanol. Cells or
sections were mounted with Aquatex mounting medium (Merck,
Darmstadt, Germany). The staining was visualized, and the images
were captured using light microscopy (Nikon eclipse E600 micro-
scope, Nikon, Tokyo, Japan). For immunoﬂuorescence, sections were
mounted with DAPI (4,6-diamidino-2-phenylindole)-containing
mounting medium (Sigma) and were examined using the Hamamatsu
NanoZoomer Digital slide scanner 2.0HT (Hamamatsu Photonics,
Bridgewater, NJ, USA). Cells were also stained with Phalloidin
(Life Technologies; 1:200 dilution) for 1 h to visualize F-Actin
ﬁlaments.
Western blotting analysis
Cells were lysed in RIPA buffer (Pierce Thermoscientiﬁc, Rockford,
IL, USA) containing protease inhibitor cocktail and phosphatase
inhibitors (Roche Diagnostics, Mannheim, Germany). The samples
were boiled in standard protein sample buffer and were subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis with 4–20%
Tris-glycine gels (Life Technologies) followed by protein transfer
onto a polyvinylidene diﬂuoride membrane. The membranes were
developed according to the standard protocols using primary and
secondary antibodies (refer to Supplementary Table 1). The bands
were visualized using ECL detection reagent (Perkin Elmer Inc.,
Waltham, MA, USA) and were photographed using the FluorChem
Figure 2 Increased ITGA11 expression in human hepatic stellate cells following TGFβ treatment. (a) Collagen I-, α-SMA- and ITGA11
(ITGA11, red; DAPI, blue)-stained human HSCs treated with medium (control) or TGFβ (5 ng ml−1). (b) Western blotting and (c) analysis of
ITGA11 and β-actin expression in control and TGFβ1-activated human HSCs, human hepatocytes (HepG2) and human monocytes (THP1).
‘nd’ denotes not detected. (d) Gene expression of ﬁbrotic parameters (Col1α1, Acta2, desmin, vimentin, TIMP1 and PDGFβR) and ITGA11
and ITGB1 in control and TGFβ-activated human HSCs, n=4. *Po0.05 and **Po0.01 versus control HSCs.
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M Imaging System (ProteinSimple, Alpha Innotech, San Leandro,
CA, USA).
Quantitative real-time PCR and RT2 proﬁler PCR array
Total RNA from cells and liver tissues was isolated using the GenElute
Total RNA Miniprep Kit (Sigma) and SV total RNA isolation system
(Promega Corporation, Madison, WI, USA), respectively, according to
the manufacturers’ instructions. The RNA concentration was
quantitated using a UV spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA). Total RNA (1 μg) was reverse transcribed
using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA).
All primers were purchased from Sigma-Genosys (Haverhill, UK).
Real-time PCR was performed using the 2× SensiMix SYBR and
Fluorescein Kit (Bioline GmbH, QT615-05, Luckenwalde, Germany),
20 ng of cDNA and pretested gene-speciﬁc primer sets (listed in
Supplementary Tables 2 and 3). The cycling conditions for the
Bio-Rad CFX384 Real-Time PCR detection system were 95 °C for
10 min, 40 cycles of 95 °C/15 s, 58 °C/15 s and 72 °C/15 s. Finally, cycle
Figure 3 ITGA11 depletion in human HSCs inhibits HSC activation. (a) Western blotting depicting ITGA11, Collagen-I and β-actin
expression in control, TGFβ-treated HSCs and TGFβ-treated ITGA11-KD (ITGA11-knockdown) HSCs. (b) Collagen-I-, α-SMA- and vimentin-
stained control and ITGA11-KD HSCs with or without TGFβ (5 ng ml−1). (c) Gene expression of ITGA11, ﬁbrotic parameters (Collagen I,
Acta2, vimentin and TIMP1), ECM-adhesion protein (Paxillin), ITGB1 and ITGA5 in control HSCs, TGFβ-treated scrambled HSCs and
ITGA11-KD HSCs, n=4. #Po0.05 and ##Po0.01 versus control HSCs. *Po0.05 and **Po0.01 versus TGFβ-treated HSCs. Control cells
were transfected with control/scrambled shRNA plasmid. ITGA11-KD cells were transfected with the ITGA11 shRNA plasmid.
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threshold (Ct) values were normalized to the reference gene GAPDH
(glyceraldehyde 3-phosphate dehydrogenase), and fold changes in
expression were calculated using the 2−ΔΔCt method. For the RT2
proﬁler array, RNA (500 ng) from ITGA11-KD cells and control cells
was reverse transcribed using the RT2 First Strand Kit (SABiosciences,
Frederick, MD, USA), and qPCR was performed using the human
ﬁbrosis PCR array (RT2 Proﬁler PCR Array PAHS-120Z, SABios-
ciences) as per the manufacturer’s instructions. Six house-keeping
genes (ACTB, B2M, GAPDH, HPRT1, RPLP0 and HGDC), RT
controls and PCR controls were included in each run. PCR array
data were analyzed using the web-based software ‘RT2 Proﬁler PCR
Array Data Analysis v. 3.5’, available at the manufacturer’s website.
ITGA11 mRNA expression in the human cohort from the
public database
ITGA11 mRNA expression was assessed in the publicly available
transcriptome data sets of liver tissue from patients with non-alcoholic
steatohepatitis (non-alcoholic fatty liver disease) (n= 72, GSE49541),
renal allograft tissue from patients after allograft renal transplantation
(n= 48, GSE25902) and lung tissue from patients with or without
interstitial lung disease (n= 219, GSE47460).
Statistical analyses
The results were expressed as the mean+s.e.m. The graphs and
statistical analyses were performed using GraphPad Prism version
5.02 (GraphPad Prism, La Jolla, CA, USA). Analyses were performed
using Student’s t-test (comparison with the control group), while
multiple comparisons between different groups were performed using
the one-way analysis of variance with the Bonferroni post hoc test.
Po0.05 was considered signiﬁcant. Correlations were assessed using
Pearson’s correlative analysis, and dot plots were generated. For
in vitro experiments, no statistical method was used to predetermine
the sample size. For in vivo experiments, the sample size was estimated
using power analysis—that is, a difference of 20% with a power of
80% (1− β) and an α of 0.05. For all in vivo studies, mice were blindly
randomized into different groups. The investigators were not blinded
to allocation for the in vivo experiments but were blinded to allocation
for immunohistochemical analyses. Quantitative data analysis was
performed in a blinded manner. No samples that were fully processed
for different assays, western blotting or immunohistochemical analysis
were excluded. No mice that completed the studies were excluded
from the analyses.
RESULTS
Upregulation of ITGA11 in the ﬁbrotic livers in CCl4-
induced mouse models
We examined the ITGA11 expression in the mouse ﬁbrotic
livers as compared with the healthy livers. Repeated
administration of CCl4 for 4 and 8 weeks in mice resulted in
extensive bridging ﬁbrosis with a substantial deposition of
Table 1 Genes differentially expressed in ITGA11-KD cells compared with control cells characterized in the Human Fibrosis
PCR Array (RT2 Proﬁler PCR Array PAHS-0120Z, SABiosciences) and analyzed using the provided RT Proﬁler PCR Array Data
Analysis v. 3.5 software
Gene symbol Refseq Description Fold regulation
Proﬁbrotic and inﬂammatory cytokines
ACTA2 NM_001613 Actin, alpha 2, smooth muscle, aorta −1.8557
CCL2 (MCP1) NM_002982 Chemokine (C-C motif) ligand 2 −4.2634
IL-1B NM_000576 Interleukin 1, beta −4.0615
Extracellular matrix, ECM remodeling and cell adhesion
COL1A2 NM_000089 Collagen, type I, alpha 2 −2.4318
MMP1 NM_002421 Matrix metallopeptidase 1 (interstitial collagenase) −60.6317
MMP3 NM_002422 Matrix metallopeptidase 3 (stromelysin 1, progelatinase) −5.0002
MMP9 NM_004994 Matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase) −1.948
TIMP1 NM_003254 TIMP metallopeptidase inhibitor 1 −2.0167
TIMP3 NM_000362 TIMP metallopeptidase inhibitor 3 −2.6427
PLAT NM_000930 Plasminogen activator, tissue −1.9079
PLAU NM_002658 Plasminogen activator, urokinase −3.6351
SERPINE1 NM_000602 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 −2.2377
ITGA2 NM_002203 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) −4.8299
Signal transduction (TGFβ superfamily and transcription factors)
CEBPB NM_005194 CCAAT/enhancer binding protein (C/EBP), beta −1.9616
STAT1 NM_007315 Signal transducer and activator of transcription 1 −1.8557
TGFBR1 NM_004612 Transforming growth factor, beta receptor 1 −1.9752
TGFBR2 NM_003242 Transforming growth factor, beta receptor 2 −1.948
TGIF1 NM_003244 TGFB-induced factor homeobox 1 −2.0591
THBS1 NM_003246 Thrombospondin 1 3.1123
THBS2 NM_003247 Thrombospondin 2 −1.8947
Bold characters indicate genes upregulated or downregulated by ⩾1.8-fold.
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collagen I and HSC activation (increased desmin expression)
compared with olive-oil-treated non-ﬁbrotic control livers
(Figure 1a and Supplementary Figure S1). The gene expression
of major ﬁbrotic parameters, including Col1a1 (Collagen I),
Des (desmin), Acta2 (α-SMA), Col3a1 (Collagen-III), TGFβ,
Timp1 (tissue inhibitor of matrix metalloproteases), Mmp9 and
Mmp13 (matrix metalloproteases 9 and 13) and PdgfβR
(platelet-derived growth factor receptor beta), were signiﬁcantly
increased in the CCl4-treated ﬁbrotic livers versus olive-oil-
treated control livers (Figure 1b). Importantly, both the protein
and gene expression levels of Itga11 were correlatively upregu-
lated with an increasing degree of liver ﬁbrosis (collagen-I and
Role of ITGA11 in ﬁbrotic diseases
R Bansal et al
8
Experimental & Molecular Medicine
desmin), and the expression was localized in the areas of active
ﬁbrogenesis (Figures 1a–c). Because the ITGA11 subunit forms
a dimer with the ITGB1 subunit (Integrin beta 1), we also
assessed the expression of ITGB1 and observed higher
expression of Itgb1 (Integrin beta 1) mRNA expression in
8-weeks CCl4-treated ﬁbrotic livers as compared with the
control livers (P= 0.06) (Figure 1b). Additionally, we observed
very low expression of ITGA11 in normal healthy livers
(Figure 1a) and other normal mouse organs—that is, the
heart, kidneys, lungs and spleen—mainly conﬁned to the
collagen-I-positive regions (Supplementary Figure S2).
Upregulation and myoﬁbroblast-speciﬁc localization of
ITGA11 expression in the human ﬁbrotic livers
In the human cirrhotic livers, ITGA11 was highly over-
expressed and speciﬁcally co-localized with α-SMA-positive
HSCs (Figure 1d). Analysis in non-alcoholic fatty liver disease
patients showed a signiﬁcant induction of ITGA11 expression
(Po0.04) in the advanced liver ﬁbrosis stages F3 or F4 (severe
ﬁbrosis, n= 32) compared with stage F0 or F1 (mild ﬁbrosis,
n= 40) (Figure 1e) as determined from transcriptome data
analysis (GEO accession number: GSE49541).
Induction of ITGA11 expression following TGFβ-mediated
HSC activation
To establish that ITGA11 is speciﬁcally induced in primary
human activated HSCs (liver myoﬁbroblasts), we examined its
expression in TGFβ-activated HSCs compared with
non-activated control HSCs. As shown in Figures 2a and b,
upon TGFβ-mediated HSC activation, ITGA11 protein
expression was signiﬁcantly increased concomitantly with
collagen-I and the myoﬁbroblast-speciﬁc marker α-SMA. By
contrast, ITGA11 expression remained undetectable in human
hepatocytes (HepG2) and human monocytes (THP1)
(Figures 2b and c). Furthermore, mRNA analysis showed
marked induction of several genes associated with the
myoﬁbroblastic phenotype, including Col1a1, Acta2, Desmin,
Vimentin, TIMP1 and PDGFβR, and ITGA11 and ITGB1
(Figure 2d).
ITGA11 depletion in HSCs attenuates HSC activation and
differentiation
To implicate ITGA11 in HSC activation, we generated human
HSCs with stable ITGA11 knockdown (ITGA11-KD) using
shRNA-ITGA11 and evaluated whether the loss of ITGA11
affects their phenotype and TGFβ-mediated activation and
differentiation. The knockdown of ITGA11 was conﬁrmed
using western blotting and qPCR, with 90% reduction in
ITGA11 expression compared with scrambled-shRNA-
transfected control HSCs (Figures 3a and c). Signiﬁcantly, we
found that ITGA11-KD HSCs strongly inhibited TGFβ-induced
differentiation (α-SMA) and ECM production (collagen-I and
vimentin) compared with control (scrambled shRNA) HSCs
(Figures 3b and c). ITGA11 knockdown signiﬁcantly down-
regulated mRNA transcripts of major ﬁbrotic parameters such
as collagen-I, Acta2, Vimentin, TIMP1 and Paxillin (ECM
adhesion protein), whereas no effect on ITGB1 and ITGA5
mRNA levels was observed (Figure 3c). Notably, scrambled-
shRNA-transfected control HSCs demonstrated increased
α-SMA expression (Figure 3c) compared with control HSCs
(non-transfected) as shown in Figure 2d.
We further analyzed ITGA11-KD and control HSCs
for the mRNA proﬁling of 84 ﬁbrosis parameters using the
RT2 proﬁler human ﬁbrosis array. Interestingly, we
found the downregulation of the following 19 ﬁbrosis-related
genes: (a) pro-ﬁbrotic and inﬂammatory cytokines, for
example, Acta2, MCP1 (or CCL2) and interleukin-1β; (b)
ECM-remodeling and adhesion genes, for example, Collagen
1A2, MMP1, MMP3, MMP9, TIMP1, TIMP3, PLAT,
PLAU, SERPINE1 and ITGA2; and (c) TGFβ superfamily
genes, for example, C/EBP, STAT1, TGFBR1, TGFBR2,
TGIF1 and THBS2 (Table 1). These ﬁndings suggest that
ITGA11 indeed regulates HSC activation at different
levels. Notably, ITGA11 depletion inhibited the expression of
TGFβ receptors (TGFβR1 and TGFβR2) and TGIF1
(TGFβ inducing factor 1), implicating a role of ITGA11 in
the negative feedback regulation of the TGFβ-signaling pathway
(Table 1).
Figure 4 ITGA11 depletion in HSCs inhibits phenotypic transformation of HSCs. (a) Percentage of wound closure (24 h) by control HSCs
and ITGA11-KD HSCs under different conditions, n=4. #Po0.05, ##Po0.01 versus control or ITGA11-KD HSCs; *Po0.05.
Representative images (b) and quantitative analysis (c) of 3D collagen-I gel contraction containing control versus ITGA11-KD HSCs treated
with or without TGFβ (5 ng ml−1), n=4. ##Po0.01 versus control HSCs; **Po0.01 versus TGFβ-treated HSCs. (d) Percentage of cell
viability of control HSCs and ITGA11-KD HSCs with or without TGFβ (5 ng ml−1) at different time points (0, 24 and 48 h) as assessed
using the Alamar Blue assay. n=4. #Po0.05 versus control; *Po0.05 and **Po0.01 versus control or TGFβ-treated HSCs. (e) ITGA11-
KD and control HSCs stained with phalloidin (red, ﬁrst column), ITGA11 (green, second column); third column, merged image; fourth
column, magniﬁed merged image (depicting co-localization), and arrows depict the ITGA11/phalloidin co-stained protrusions. Nuclei are
stained blue with DAPI. (f) AFM images depicting the adhesion of stained control HSCs and ITGA11-KD HSCs. The upper panel depicts
microscopic images, the middle panel depicts AFM images and the bottom panel depicts the magniﬁed edges. The right panel shows the
height of cells (average± s.d., n=4) as measured by AFM. (g) Control (ﬁrst column) and ITGA11-KD (second column) HSCs stained with
vinculin (green, upper panel) and phalloidin (red, middle panel); lower panel, merged image. The third column shows the magniﬁed
vinculin-stained images. Nuclei are stained blue with DAPI. Control cells were transfected with control/scrambled shRNA plasmid. ITGA11-
KD cells were transfected with the ITGA11 shRNA plasmid.
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ITGA11 depletion in HSCs inhibits the phenotypic
transformation of HSCs
Because HSCs can migrate to the sites of tissue injury during
ﬁbrogenesis and differentiate into contractile myoﬁbroblasts
that promote liver stiffness, we examined the effect of ITGA11
knockdown on migration using wound-healing assays and
contractility of HSCs using the 3D collagen contraction assay.
ITGA11-KD HSCs displayed attenuated migration after 24 h
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compared with control HSCs upon migratory stimulation
with 10% FBS (approximately 30% inhibition) or TGFβ
(approximately 60% inhibition) (Figure 4a and
Supplementary Figure S3). Furthermore, ITGA11-KD HSCs
displayed signiﬁcantly diminished collagen gel contraction
upon TGFβ activation compared with scrambled control HSCs
(approximately 60% inhibition; Figures 4b and c). Because
these effects can be related to differences in proliferation, we
performed the Alamar Blue assay at different incubation times
(0, 24 and 48 h) with or without TGFβ. We observed
approximately 10% inhibition in cell proliferation after 24 h
of TGFβ incubation and approximately 20% inhibition in cell
proliferation after 48 h of incubation (Figure 4d). Therefore,
the differences observed in wound-healing assays and contrac-
tion assays (60% inhibition) could partially reﬂect the reduced
proliferative activity of ITGA11-KD HSCs (Figures 4a–d).
To further investigate the signiﬁcance of ITGA11 on the
functional characteristics of HSCs, we studied their adhesion to
the surface and changes in protrusions. We performed
phalloidin/ITGA11 co-immunostaining and found that
ITGA11-KD HSCs have signiﬁcantly reduced actin ﬁbers and
focal adhesion points compared with control scrambled HSCs
(Figure 4e). To further conﬁrm these changes in adhesion, we
performed AFM to visualize the detailed focal adhesions. As
shown in Figure 4f, many focal adhesions were present in the
scrambled control HSCs as compared with ITGA11-KD HSCs
where the cellular edges were blunted, indicating the loss of
focal adhesions and poor adhesion to the surface. We also
quantiﬁed the cell height from the surface because if the cells
are tightly adherent, the cells have less height compared with
the weakly adhered cells. Interestingly, we observed that the
height of the control scrambled HSCs was signiﬁcantly lower
than that of ITGA11-KD HSCs (1.10± 0.29 versus
1.465± 0.54 μm) (Figure 4f), reﬂecting an important role of
ITGA11 in cellular adhesion. In addition, we performed
vinculin and phalloidin staining on TGFβ-activated control
scrambled HSCs and ITGA11-KD HSCs and observed highly
signiﬁcantly reduced vinculin and phalloidin staining as shown
in Figure 4g. Notably, vinculin and phalloidin staining was
signiﬁcantly differently localized in ITGA11-KD cells as com-
pared with control HSCs as depicted in higher magniﬁcation
images (Figure 4g). These data strongly demonstrate that
ITGA11 is a functionally and distinctively active receptor in
the regulation of the activation and differentiation of HSCs and
mediate the contraction, migration and adhesion of HSCs.
Crosstalk between ITGA11 and the Hedgehog signaling
pathway
Recently, it has been shown that myoﬁbroblasts mainly
originate from Gli1+ (glioma-associated oncogene
homolog 1) perivascular progenitor cells.32 Because Gli1 is a
transcription factor of the hedgehog pathway, we investigated
the effect of ITGA11-KD on the expression levels of hedgehog
pathway-related components—that is, sonic hedgehog ligand
(SHH), patched-1 receptor (PTCH1), Smoothened (SMO), a
downstream protein in the pathway, and signaling molecules
Gli1, Gli2 transcription factors and sex-determining region Y
box 9 (Sox9) in HSCs. Interestingly, we found that the mRNA
expression levels of hedgehog pathway-related components are
highly signiﬁcantly inhibited following ITGA11 knockdown
(Figure 5a). Furthermore, TGFβ-induced expression of Gli1
and Sox9 was signiﬁcantly inhibited in ITGA11-KD HSCs as
compared with control scrambled HSCs (Figure 5b), suggesting
that ITGA11 mediates its effect via the hedgehog pathway, or
ITGA11 may be involved in the downstream hedgehog
signaling pathway and positively regulate Gli1 and Sox9
expression. To study the direct involvement of hedgehog and
ITGA11, we incubated control and ITGA11-KD HSCs with
5 μgml− 1 of Shh ligand and investigated ITGA11 gene
expression. We found control HSCs showed the induction in
ITGA11 expression following incubation with Shh ligand
compared with ITGA11-KD, further demonstrating that
ITGA11 is downstream of the hedgehog signaling pathway
and regulates HSC activation and differentiation (Figure 5c).
We further examined the expression of Gli1 on α-SMA-positive
myoﬁbroblasts and conﬁrmed the perivascular co-localization
of Gli1 and α-SMA (Figure 5d), corroborating the ﬁndings of a
recent study.32
Figure 5 Myoﬁbroblastic localization of Gli1 and the effect of hedgehog inhibition on TGFβ-activated human HSCs in vitro and human liver
slices ex vivo. (a) Gene expression of hedgehog pathway-related genes (Shh, Ptch1, Smo, Gli1, Gli2 and Sox9) in ITGA11-KD HSCs versus
control HSCs, n=3. **Po0.01 represents signiﬁcance versus control HSCs. (b) Gene expression of hedgehog pathway-related genes (Sox9
and Gli1) in TGFβ-treated ITGA11-KD HSCs versus TGFβ-treated control HSCs, n=4. #Po0.05 and ##Po0.01 versus control HSCs
(dashed line); *Po0.05 and **Po0.01 versus TGFβ-treated HSCs. (c) Gene expression of ITGA11 in control HSCs and ITGA11-KD HSCs
with or without Shh (5 μg ml−1), n=3. #Po0.01 versus Shh-treated HSCs, **Po0.01 versus control HSCs. (d) α-SMA and Gli1 co-
immuno-stained human liver sections. Gli1 (red, ﬁrst column), α-SMA (green, second column) and merged image (third column). Fourth
column shows the magniﬁed image depicting co-localization. Nuclei are stained blue with DAPI. (e) Collagen-I- and vimentin-stained HSCs
treated with or without TGFβ (5 ng ml−1)±10 μM of the hedgehog inhibitor (LDE225). Gene expression of ﬁbrotic parameters collagen-I, α-
SMA and vimentin in HSCs treated with medium alone, TGFβ (5 ng ml−1)±10 μM LDE225, n=3. #Po0.05, ##Po0.01 versus the control
cells; *Po0.05 versus TGFβ-treated cells. (f) Graph depicts % 3D collagen-I gel contraction after 24, 48 and 72 h of treatment with or
without TGFβ (5 ng ml−1)±10 μM LDE225, n=3. #Po0.05, ##Po0.01 versus control cells; *Po0.05 versus TGFβ-treated cells. Gene
expression of Acta2, TIMP1, PDGFβR and Collagen-I (g) and ITGA11, Sox9, Gli1 and ITGA5 (h) in the slices obtained from ﬁbrotic livers
from human patients incubated with medium (control) or 10 or 15 μM LDE225. n=3 patients (3 slices each). *Po0.05 and **Po0.01
versus control group. Control cells were transfected with control/scrambled shRNA plasmid. ITGA11-KD cells were transfected with the
ITGA11 shRNA plasmid.
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Hedgehog pathway inhibition attenuates ﬁbrotic parameters
in human HSCs in vitro and human liver slices ex vivo
To further understand the mechanism involved in
ITGA11-mediated regulation of myoﬁbroblast differentiation,
we examined the effect of a selective hedgehog signaling
pathway inhibitor, LDE225 (or Erismodegib), on human
HSC activation in vitro in human HSCs and ex vivo in
human liver slices. Treatment of HSCs with LDE225
led to a signiﬁcant reduction in TGFβ-induced α-SMA,
collagen I and vimentin gene and protein expression
(Figure 5e and Supplementary Figure S4). Because
ITGA11-KD cells had an attenuated capacity of collagen
production, we examined the effect of hedgehog inhibition
on HSC contraction and found that LDE225 (10 μM) signiﬁ-
cantly reduced TGFβ-induced collagen gel contraction
(Figure 5f).
Importantly, LDE225 (10 or 15 μM) treatment of
ex vivo human liver slices resulted in a signiﬁcant inhibition
of ﬁbrotic genes (Acta2, TIMP-1 and PDGFβR) (Figure 5g)
and attenuation of the expression of ITGA11 and ITGA5
(angiogenesis parameters) and hedgehog signaling
molecules Sox9 and Gli1 (Figure 5h). Altogether, these results
conﬁrm a potential link between ITGA11 and the hedgehog
pathway.
Figure 6 Effect of hedgehog inhibition in an acute CCl4-induced liver injury mouse model. (a) Representative photomicrographs and
quantitative analysis of collagen-I- and desmin-stained liver sections from normal (olive-oil-treated), vehicle-treated CCl4 and LDE225-
treated CCl4 mice. (b) Gene expression in the livers of different treated groups, n=5 per group. #Po0.05 and ##Po0.01 versus the
olive-oil-treated normal group; *Po0.05 versus CCl4-treated vehicle group. (c) The serum ALT levels of different treated groups. n=5 per
group. ##Po0.01 versus olive-oil treated control group; P=0.06 versus CCl4-treated vehicle group.
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Inhibition of the hedgehog pathway ameliorates ﬁbrogenesis
in vivo in an acute liver injury mouse model
We further investigated the effect of a selective hedgehog
signaling pathway inhibitor, LDE225 (or Erismodegib), in vivo
in an acute liver ﬁbrogenesis mouse model. In the
CCl4-induced acute liver injury mouse model, hedgehog
inhibitor signiﬁcantly inhibited collagen-I, desmin and
α-SMA protein expression (Figure 6a and Supplementary
Figure S5). In addition, we observed a signiﬁcant reduction
in the mRNA expression of (a) ﬁbrogenic parameters (Col1a1,
Acta2, Desmin, Vimentin and Tgfβ), (b) angiogenesis markers
(Vegf, Itga5 and Cd31) and (c) hedgehog pathway-related genes
(Gli1 and Sox9) (Figure 6b) with signiﬁcantly reduced ITGA11
expression (Figure 6b). We also observed a reduction
(P= 0.06) in alanine aminotransferase levels following
treatment with LDE225, suggesting the attenuation of liver
inﬂammation (Figure 6c).
Myoﬁbroblast-speciﬁc localization of ITGA11 in mouse and
human ﬁbrotic kidneys
Because renal myoﬁbroblasts are the major mediator of ECM
deposition and scar tissue formation in kidney ﬁbrosis, we
examined the role of ITGA11 in human ﬁbrotic kidneys and
UUO kidney ﬁbrosis mouse models. After 7 days of UUO,
mice developed extensive renal ﬁbrosis as shown by the
substantial deposition of collagen-I and enhanced α-SMA
expression in the ﬁbrotic kidneys compared with that in the
contralateral control kidneys (Figure 7a). There was strong
expression of ITGA11 in the UUO kidneys in the tubulointer-
stitium, glomerular and perivascular membrane, the areas
where α-SMA was also highly expressed. By contrast, ITGA11
was weakly expressed in the glomerular mesangium in the
contralateral kidneys (Figure 7a). Furthermore, in the ﬁbrotic
kidneys from UUO (3 and 7 days), we observed increased
mRNA expression of Col1a1, Acta2, Col3a1 and Itga11
(Figure 7a). In human ﬁbrotic kidneys, there was a signiﬁcant
increase in ITGA11 expression, which was speciﬁcally
co-localized with α-SMA-positive cells, including vascular
smooth muscle cells and interstitial ﬁbroblasts (Figure 7b).
We also correlated the interstitial ﬁbrosis and tubular atrophy
score with ITGA11 expression using clinical transcriptomic
data analysis (GEO accession number: GSE25902) and found
that ITGA11 expression was signiﬁcantly (Po0.03) induced at
score 3 compared with that at scores 0–2 (Figure 7c).
Myoﬁbroblast-speciﬁc localization of ITGA11 in the human
ﬁbrotic lungs
To further extend our ﬁndings, we analyzed the ITGA11
expression in ﬁbrotic lungs from patients with idiopathic
pulmonary ﬁbrosis. We found a signiﬁcant induction in the
ITGA11 expression in the ﬁbrotic lungs as compared with the
healthy lungs, and ITGA11 expression was found to be
speciﬁcally co-localized with α-SMA-positive myoﬁbroblasts
(Figure 7d). Furthermore, we found a highly signiﬁcant
increase in ITGA11 mRNA expression in the lungs from
idiopathic pulmonary ﬁbrosis patients (Po0.001, n= 123) as
compared with normal lungs (n= 96), as assessed by tran-
scriptome data analysis (GEO accession number: GSE47460)
(Figure 7e). In addition, we assessed ITGA11 expression in
normal and ﬁbrotic human lung slices and found an increased
expression of ﬁbrotic parameters (Collagen-I, Vimentin and
TIMP1) with concomitant induction in the ITGA11 expression
(Figure 7f).
DISCUSSION
The present study established the signiﬁcance of integrin
alpha11 (ITGA11), a collagen I binding receptor, in the
regulation of myoﬁbroblast phenotypic differentiation during
ﬁbrotic diseases. ITGA11 expression was substantially induced
in myoﬁbroblasts in the ﬁbrotic liver, kidneys and lungs and
co-localized with α-SMA in mouse models and human patient
samples. Interestingly, the knockdown of ITGA11 in
myoﬁbroblasts (or activated HSCs) strongly inhibited their
activation, differentiation, migration and contractility. Gene
array showed that several ﬁbrosis-related genes were signiﬁ-
cantly reduced after knockdown of ITGA11 in HSCs. Further-
more, our data revealed that the hedgehog signaling pathway
contributed to the regulation of ITGA11 expression, and
inhibition of the hedgehog pathway using a speciﬁc inhibitor
attenuated early liver ﬁbrogenesis in mice and inhibited ﬁbrotic
parameters in ex vivo human liver slices.
Excessive tissue scarring or ﬁbrosis is a common feature of
most chronic diseases.15 During tissue injury, environmental
cues and various growth factors lead to the activation and
differentiation of myoﬁbroblasts, which are the major ECM-
producing ﬁbrogenic cells.12 Therefore, therapeutic interven-
tion leading to inactivation of the myoﬁbroblastic phenotype or
reverting these cells to the quiescent state would be a rational
approach to treat ﬁbrotic diseases. Integrins are overexpressed
in different cell types in response to an injury and interact with
ECM proteins, allowing the cells to attach, migrate and
proliferate.16 During ﬁbrogenesis, myoﬁbroblasts produce
ECM constituents, including collagens, and express integrin
receptors that interact and signal via ECM proteins. Recently,
integrin αv has been shown to regulate myoﬁbroblast
differentiation.17,20 As shown in the current study, ITGA11
was highly upregulated in myoﬁbroblasts during ﬁbrogenesis
(liver, kidney and pulmonary ﬁbrosis as shown in mouse
models and human ﬁbrotic tissues). Furthermore, negligible
expression of ITGA11 was found in healthy mouse and human
tissues, suggesting that the inhibition of this receptor likely has
a minimal impact on normal tissues. Strikingly, the patient
transcriptomic data analysis showed a signiﬁcant induction of
ITGA11 at increasing stages of ﬁbrosis in patients with non-
alcoholic fatty liver disease, idiopathic pulmonary ﬁbrosis and
interstitial kidney ﬁbrosis. Furthermore, our gene expression
data in freshly isolated lung specimens from patients showed
higher ITGA11 expression levels in ﬁbrotic lungs than those in
non-ﬁbrotic lungs. These data strongly highlight ITGA11 as a
promising marker in ﬁbrogenesis that could be used to identify
and segregate ﬁbrosis stages in different organs.
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During ﬁbrogenesis, TGFβ is one of the key growth factor
involved in disease progression by activated ﬁbroblasts.11,33
TGFβ can increase the expression of integrins,34 and similarly,
integrins can modulate the TGFβ/Smad pathways directly or
indirectly via different mechanisms.17 In the current study,
ITGA11 expression in HSCs was highly upregulated in
response to TGFβ activation (Figures 2a–c), corroborating with
the previous ﬁndings showing TGFβ-mediated regulation of
ITGA11 in Smad- and Sp1-dependent manner.27 Furthermore,
stable knockdown of ITGA11 in HSCs downregulated TGFβ
Figure 7 Integrin alpha 11 (ITGA11) overexpression in the UUO model of kidney ﬁbrosis in mice and in ﬁbrotic human kidneys and
ﬁbrotic lung tissues. (a) Collagen-I-, α-SMA- and ITGA11-stained kidney sections obtained from sham- and 7 days UUO-operated mice
(n=4 per group). Gene expression of ﬁbrotic parameters (Col1A1, Acta2 and Col3A1) and ITGA11 in the kidneys from contralateral, 3-day
and 7-day UUO-operated mice, n=4 per group. *Po0.05 and **Po0.01 versus contralateral kidneys. (b) α-SMA and ITGA11
co-immunostained human ﬁbrotic kidney sections (n=4 per group). Upper, ITGA11 (red); middle, α-SMA (green); bottom, merged image.
Nuclei are stained blue using DAPI. The lower panel depicts the magniﬁed image. (c) The ITGA11 mRNA expression levels extracted from
publicly available transcriptome proﬁling data sets (www.ncbi.nlm.nih.gov/geo). Kidney tissues stratiﬁed according to the IFTA score: 0, no
ﬁbrosis (n=16); 1, mild ﬁbrosis (n=11); 2, moderate ﬁbrosis (n=13); 3, severe ﬁbrosis (n=8) (GSE25902), *P=0.03. (d) α-SMA and
ITGA11 co-immunostained human lung sections (n=5 per group). Upper, ITGA11 (red); middle, α-SMA (green); bottom, merged image.
Nuclei are stained blue using DAPI. (e) The ITGA11 mRNA expression levels were extracted from publicly available transcriptome proﬁling
data sets (www.ncbi.nlm.nih.gov/geo). Lung tissues with idiopathic pulmonary ﬁbrosis (n=123) compared with normal controls (n=96)
(GSE47460). *Po0.001 versus normal lungs. (f) Heat map representation of the gene expression of ITGA11, Col1A1, Vimentin and
TIMP1 in human lung slices. N1–N5 and F1–F5 denote normal and ﬁbrotic samples, respectively.
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superfamily genes (CEBPB, TGFBR1, TGFBR2 and TGIF1),
demonstrating a strong negative feedback regulation of the
TGFβ signaling pathway by ITGA11 in HSCs. In addition,
ﬁbrosis proﬁler array data revealed that ITGA11 knockdown in
HSCs also reduced several pro-ﬁbrotic and ECM remodeling
genes (for example, collagen-I, MMP-1, -3, -9 and TIMP-1, -3),
suggesting that ITGA11 controls ECM production and remo-
deling in HSCs. Integrins are also crucial receptors for the
maintenance of the cytoskeleton, thereby controlling cell shape,
contractility and migration. In the present study, we demon-
strate that ITGA11 knockdown in HSCs led to a signiﬁcant loss
of focal adhesion, as shown with AFM, and a reduction in a
major adhesion protein, paxillin, which regulates HSC adhesion
to the matrix. As focal adhesions are crucial for cell contractility
and migration, ITGA11 knockdown in HSCs led to reduced
collagen gel contraction and migration.
Recent data have suggested that myoﬁbroblasts in different
ﬁbrotic diseases originate from Gli1+ perivascular cells.32 Here
we also demonstrate Gli1 co-expression on perivascular αSMA-
positive myoﬁbroblasts in human ﬁbrotic livers. Gli1 is a
transcription factor of the hedgehog signaling pathway that has
an important role in ﬁbrosis, and its selective inhibition has
been shown to ameliorate liver ﬁbrosis.35 In this study,
hedgehog signaling pathway molecules (Gli1 and Sox9) were
upregulated in both TGFβ-activated HSCs and in vivo in mouse
liver ﬁbrosis model. Interestingly, hedgehog pathway-related
genes (Shh, Ptch1, Smo, Gli1, Gli2 and Sox9) were signiﬁcantly
downregulated in ITGA11-KD HSCs, and TGFβ-induced
upregulation of hedgehog signaling molecules (Sox9 and
Gli1) were attenuated in ITGA11 knockdown HSCs, indicating
an inter-relationship between the ITGA11 and hedgehog
signaling pathways. We further observed signiﬁcantly increased
expression of ITGA11 in Shh-treated control HSCs that was
completely blocked in ITGA11-KD cells, suggesting a direct
correlation between the hedgehog pathway and ITGA11.
Furthermore, treatment with a speciﬁc hedgehog inhibitor,
LDE225, reduced the expression of ITGA11 and several
ﬁbrosis-related genes in TGFβ-activated human HSCs and
CCl4-induced early liver ﬁbrogenesis mouse model. To demon-
strate the impact of hedgehog inhibition on ITGA11 in clinical
samples, we used precision-cut liver slices from patient-derived
ﬁbrotic livers.36 Interestingly, LDE225 strongly reduced the
ITGA11 expression and several ﬁbrotic genes in these slices.
These data explicitly show that the ITGA11 and hedgehog
pathways regulate each other, and the inhibition of the hedge-
hog pathway is an interesting strategy to inhibit the ITGA11
expression. Because ITGA11 positively regulates the TGFβ and
hedgehog signaling pathways, ITGA11 might be involved
downstream in these signaling pathways. However, detailed
promoter studies are required to elucidate the role of the
TGFβ/smad3 pathway and hedgehog/Gli1 pathway and invol-
vement of ITGA11 in these regulatory pathways.
In conclusion, ITGA11 is a highly promising target that is
selectively overexpressed in myoﬁbroblasts during ﬁbrotic
diseases and regulates myoﬁbroblast differentiation and key
phenotypic characteristics. Furthermore, our data uncovered
the hedgehog signaling pathway as a mediator of the ITGA11
pathway in myoﬁbroblasts in vivo and in patient ﬁbrotic tissues
ex vivo. Collectively, these data highlight the potential ther-
apeutic signiﬁcance of ITGA11 in liver ﬁbrosis and suggest that
the development of strategies to antagonize ITGA11 could lead
to the development of novel and effective therapies against
ﬁbrotic diseases.
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